{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:13:41Z","timestamp":1790374421508,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s10096-026-05436-1","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:56:59Z","timestamp":1771271819000},"page":"1837-1841","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Synergistic and additive in vitro interactions of imipenem, trimethoprim-sulfamethoxazole, amikacin, and clofazimine against clinical isolates of Nocardia wallacei"],"prefix":"10.1007","volume":"45","author":[{"given":"Yizhak","family":"Hershko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amos","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"key":"5436_CR1","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1128\/cmr.00027-21","volume":"35","author":"RM Traxler","year":"2022","unstructured":"Traxler RM et al (2022) Updated review on nocardia species: 2006\u20132021. Clin Microbiol Rev 35:2006\u20132021","journal-title":"Clin Microbiol Rev"},{"key":"5436_CR2","volume-title":"Performance standards for susceptibility testing of mycobacteria, nocardia spp., and other aerobic actinomycetes; 1st edition (CLSI supplement M62)","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2018","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2018) Performance standards for susceptibility testing of mycobacteria, nocardia spp., and other aerobic actinomycetes; 1st edition (CLSI supplement M62). CLSI, Wayne, PA"},{"key":"5436_CR3","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1093\/jac\/dkad236","volume":"78","author":"Y Hershko","year":"2023","unstructured":"Hershko Y et al (2023) Phenotypic and genotypic analysis of antimicrobial resistance in nocardia species. J Antimicrob Chemother 78:2306\u20132314","journal-title":"J Antimicrob Chemother"},{"key":"5436_CR4","doi-asserted-by":"publisher","unstructured":"Hershko Y, Rannon E, Adler A, Burstein D, Barkan D (2024) WarA, a remote homolog of NpmA and KamB from nocardia wallacei, confers broad spectrum aminoglycoside resistance in nocardia and mycobacteria. Int J Antimicrob Agents 63:107089.\u00a0https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107089","DOI":"10.1016\/j.ijantimicag.2024.107089"},{"key":"5436_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1128\/CMR.19.2.259-282.2006","volume":"19","author":"BA Brown-Elliott","year":"2006","unstructured":"Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ (2006) Clinical and laboratory features of the nocardia spp. Based on current molecular taxonomy. Clin Microbiol Rev 19:259\u2013282","journal-title":"Clin Microbiol Rev"},{"key":"5436_CR6","first-page":"1","volume":"7","author":"P Zhao","year":"2017","unstructured":"Zhao P et al (2017) Susceptibility profiles of nocardia spp. To antimicrobial and antituberculotic agents detected by a microplate Alamar blue assay. Sci Rep 7:1\u20138","journal-title":"Sci Rep"},{"key":"5436_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1128\/AAC.02770-14","volume":"59","author":"LR McTaggart","year":"2015","unstructured":"McTaggart LR, Doucet J, Witkowska M, Richardsona SE (2015) Antimicrobial susceptibility among clinical nocardia species identified by multilocus sequence analysis. Antimicrob Agents Chemother 59:269\u2013275","journal-title":"Antimicrob Agents Chemother"},{"key":"5436_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep17862","volume":"5","author":"A Hashemi-Shahraki","year":"2015","unstructured":"Hashemi-Shahraki A et al (2015) Genetic diversity and antimicrobial susceptibility of nocardia species among patients with nocardiosis. Sci Rep 5:1\u20139","journal-title":"Sci Rep"},{"key":"5436_CR9","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1007\/s10482-019-01296-2","volume":"112","author":"M Wei","year":"2019","unstructured":"Wei M, Wang P, Yang C, Gu L (2019) Molecular identification and phylogenetic relationships of clinical nocardia isolates. Antonie Van Leeuwenhoek Int J Gen Mol Microbiol 112:1755\u20131766","journal-title":"Antonie Van Leeuwenhoek Int J Gen Mol Microbiol"},{"key":"5436_CR10","first-page":"215","volume":"1","author":"MG Orfanakis","year":"1972","unstructured":"Orfanakis MG, Wilcox HG, Smith CB (1972) Vitro studies of the combined effect of ampicillin and sulfonamides. Microbiology 1:215\u2013220","journal-title":"Microbiology"},{"key":"5436_CR11","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1128\/AAC.5.3.344","volume":"5","author":"M Finland","year":"1974","unstructured":"Finland M, Bach MC, Garner C, Gold O (1974) Synergistic action of ampicillin and erythromycin against nocardia asteroides: effect of time of incubation. Antimicrob Agents Chemother 5:344\u2013353","journal-title":"Antimicrob Agents Chemother"},{"key":"5436_CR12","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1128\/AAC.24.5.810","volume":"24","author":"ME Gombert","year":"1983","unstructured":"Gombert ME, Aulicino TM (1983) Synergism of Imipenem and Amikacin in combination with other antibiotics against nocardia asteroides. Antimicrob Agents Chemother 24:810\u2013811","journal-title":"Antimicrob Agents Chemother"},{"key":"5436_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/jac\/24.1.39","volume":"24","author":"ME Gombert","year":"1989","unstructured":"Gombert ME, Dubouchet L, Aulicino TM, Berkowitz LB (1989) Antimicrobial synergism in the therapy of experimental cerebral nocardiosis. J Antimicrob Chemother 24:39\u201343","journal-title":"J Antimicrob Chemother"},{"key":"5436_CR14","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1128\/AAC.48.3.832-837.2004","volume":"48","author":"A Gomez-Flores","year":"2004","unstructured":"Gomez-Flores A et al (2004) In vitro and in vivo activities of antimicrobials against nocardia Brasiliensis. Antimicrob Agents Chemother 48:832\u2013837","journal-title":"Antimicrob Agents Chemother"},{"key":"5436_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.2174\/156720110791560946","volume":"7","author":"NA Espinoza-Gonzalez","year":"2010","unstructured":"Espinoza-Gonzalez NA et al (2010) Evaluation of the combined therapy of DA-7218, a new Oxazolidinone, and Trimethoprim\/ sulfamethoxazole in the treatment of experimental actinomycetoma by nocardia Brasiliensis. Curr Drug Deliv 7:225\u2013229","journal-title":"Curr Drug Deliv"},{"key":"5436_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/j.1399-3062.2010.00588.x","volume":"13","author":"MF Tripodi","year":"2011","unstructured":"Tripodi MF et al (2011) In vitro activity of multiple antibiotic combinations against nocardia: relationship with a short-term treatment strategy in heart transplant recipients with pulmonary nocardiosis. Transpl Infect Dis 13:335\u2013343","journal-title":"Transpl Infect Dis"},{"key":"5436_CR17","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/j.1365-4632.2010.04748.x","volume":"50","author":"M Ameen","year":"2011","unstructured":"Ameen M, Vargas F, Arenas R, Mercado EV (2011) del. Successful treatment of nocardia actinomycetoma with meropenem and Amikacin combination therapy. Int J Dermatol 50:443\u2013445","journal-title":"Int J Dermatol"},{"issue":"1","key":"5436_CR18","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.01849-20","volume":"65","author":"K Chew","year":"2020","unstructured":"Chew K, Lip et al (2020) In vitro susceptibility of Nocardia farcinica to the antimycobacterial drug Clofazimine. Antimicrob Agents Chemother 65(1):10\u20131128","journal-title":"Antimicrob Agents Chemother"},{"key":"5436_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.00072-18","volume":"62","author":"J Luo","year":"2018","unstructured":"Luo J et al (2018) In vitro activity of Clofazimine against nontuberculous mycobacteria isolated in Beijing, China. Antimicrob Agents Chemother 62:1\u20139","journal-title":"Antimicrob Agents Chemother"},{"key":"5436_CR20","doi-asserted-by":"publisher","first-page":"106509","DOI":"10.1016\/j.ijantimicag.2021.106509","volume":"59","author":"S Kim","year":"2022","unstructured":"Kim S et al (2022) Evaluating the effect of Clofazimine against Mycobacterium tuberculosis given alone or in combination with pretomanid, bedaquiline or linezolid. Int J Antimicrob Agents 59:106509","journal-title":"Int J Antimicrob Agents"},{"key":"5436_CR21","doi-asserted-by":"publisher","first-page":"6324","DOI":"10.1128\/AAC.01505-12","volume":"56","author":"J Van Ingen","year":"2012","unstructured":"Van Ingen J et al (2012) In vitro synergy between Clofazimine and Amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother 56:6324\u20136327","journal-title":"Antimicrob Agents Chemother"},{"key":"5436_CR22","volume-title":"Susceptibility testing of mycobacteria, nocardia spp., and other aerobic actinomycetes; approved Standard \u2013 Second edition (CLSI document M24-A2)","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2011","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2011) Susceptibility testing of mycobacteria, nocardia spp., and other aerobic actinomycetes; approved Standard \u2013 Second edition (CLSI document M24-A2). CLSI, Wayne, PA"},{"key":"5436_CR23","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1128\/JCM.01121-14","volume":"52","author":"CD Doern","year":"2014","unstructured":"Doern CD (2014) When does 2 plus 2 equal 5? A review of antimicrobial synergy testing. J Clin Microbiol 52:4124\u20134128","journal-title":"J Clin Microbiol"},{"key":"5436_CR24","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1128\/AAC.34.9.1766","volume":"34","author":"ME Gombert","year":"1990","unstructured":"Gombert ME, Berkowitz LB, Aulicino TM, DuBouchet L (1990) Therapy of pulmonary nocardiosis in immunocompromised mice. Antimicrob Agents Chemother 34:1766\u20131768","journal-title":"Antimicrob Agents Chemother"},{"key":"5436_CR25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.mayocp.2011.11.016","volume":"87","author":"JW Wilson","year":"2012","unstructured":"Wilson JW (2012) Nocardiosis: updates and clinical overview. Mayo Clin Proc 87:403\u2013407","journal-title":"Mayo Clin Proc"},{"key":"5436_CR26","doi-asserted-by":"publisher","unstructured":"Clark NM, and AST Infectious Diseases Community of Practice (2009) Nocardia in solid organ transplant recipients. Am J Transpl 9:S70\u2013S77.\u200f\u00a0https:\/\/doi.org\/10.1111\/j.1600-6143.2009.02896.x","DOI":"10.1111\/j.1600-6143.2009.02896.x"},{"key":"5436_CR27","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1093\/cid\/cix124","volume":"64","author":"D Lebeaux","year":"2017","unstructured":"Lebeaux D et al (2017) Outcome and treatment of nocardiosis after solid organ transplantation: new insights from a European study. Clin Infect Dis 64:1396\u20131405","journal-title":"Clin Infect Dis"},{"key":"5436_CR28","doi-asserted-by":"crossref","unstructured":"Yetmar ZA et al (2023) Risk factors and outcomes of nocardiosis in hematopoietic stem cell transplantation recipients. Transplant Cell Ther 29:206.e1-206.e7","DOI":"10.1016\/j.jtct.2022.12.004"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05436-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-026-05436-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-026-05436-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:37:24Z","timestamp":1782862644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-026-05436-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5436"],"URL":"https:\/\/doi.org\/10.1007\/s10096-026-05436-1","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"30 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}